November 8, 2007 . bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has announced its plans to open a subsidiary in Algeria in early 2008. The new subsidiary, based in Algiers, will enhance bioMérieux’s presence in Africa and illustrates the company’s international expansion strategy.
The news was announced at an event held today during Paris’ JIB international biologists congress, which is honoring Algeria this year. “Your country is making significant advances in its healthcare system. After over 30 years of collaboration, by creating this subsidiary in Algeria, we hope to play an integral role in its development,” Alain Mérieux, president of bioMérieux, declared to representatives of the Algerian Ministry of Health, Population and Hospital Reform.
As part of Algeria’s 2005-2009 Healthcare Development Program, the country will create over a hundred healthcare facilities. bioMérieux will provide its expertise in the fight against infectious diseases and contribute to the scientific training of healthcare professionals. In particular, bioMérieux intends to play a major part in protecting patients from healthcare-associated infections in Algeria, drawing on its unique offer in microbiology.
About bioMérieux
Advancing Diagnostics to Improve Public Health
A world leader in the field of in vitro diagnostics for over 40 years, bioMérieux is present in more than 150 countries through 35 subsidiaries and a large network of distributors. In 2006, revenues reached €1.037 billion with 83% of sales outside of France.
bioMérieux provides diagnostic solutions (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on Eurolist by Euronext. For more information, visit www.biomerieux.com.
bioMérieux Contacts
bioMérieux
Hervé Laurent
Tel: + 33 4 78 87 22 37
investor.relations@eu.biomerieux.com
LT Value
Nancy Levain
Tel: + 33 1 44 50 39 30
nancy.levain@ltvalue.com
Media Relations
bioMérieux
Koren Wolman-Tardy
Tel: + 33 4 78 87 20 08
media@eu.biomerieux.com
Image Sept
Laurence Heilbronn
Tel: + 33 1 53 70 74 64
lheilbronn@image7.fr
Tiphaine Hecketsweiler
Tel: + 33 1 53 70 74 59
thecketsweiler@image7.fr